June 15, 2022
Article
“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.
May 14, 2022
Article
Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.
March 25, 2022
Article
According to Dreicer, standard treatment in this setting for most patients should include androgen deprivation therapy (ADT) in combination with 1 or 2 other agents vs ADT therapy alone.
February 25, 2022
Article
The addition of lenvatinib to pembrolizumab did not improve overall survival in patients with advanced urothelial carcinoma.